NCT06693908

A Study to Evaluate the Activity, and Safety of Vixarelimab in Participants With Moderate to Severe Active Ulcerative Colitis

A Phase Ic Open-label Study to Evaluate the Pharmacodynamic Effects, Pharmacokinetics, and Safety of Vixarelimab in Patients With Moderate to Severe Active Ulcerative Colitis

• Status: Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 24 (estimated)
• Sponsor: Genentech, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study aims to evaluate the pharmacodynamic (PD) effects of vixarelimab in the gut of participants with active moderate to severe ulcerative colitis (UC).

Conditions

• Moderate to Severe Ulcerative Colitis

Interventions

Type	Name	Description
DRUG	Vixarelimab	Vixarelimab will be administered as per the schedule specified.

Timeline

• Start date: 2025-03-31
• Primary completion: 2026-06-09
• Completion: 2026-08-16
• First posted: 2024-11-18
• Last updated: 2026-04-17

Locations

1 site across 1 country: Germany